Kintara Therapeutics Inc (KTRA)

[undtrdr]

DelMar's VAL-083 Demonstrates Promise in the Treatment of Non-Small Cell Lung Cancer and Ovarian Cancer
MD Anderson Researchers Presented New Pre-clinical Data Today at the American Association of Cancer Research (AACR) Annual Meeting

09:00 ET from DelMar Pharmaceuticals, Inc.


VANCOUVER, British Columbia and MENLO PARK, Calif., April 18, 2016 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the Company's collaborators from the University of Texas MD Anderson Cancer Center (MD Anderson) presented new pre-clinical data supporting the promising potential of its lead anti-cancer product candidate, VAL-083 (dianhydrogalactitol), in the treatment of non-small cell lung cancer (NSCLC) and ovarian cancer.

Abstract (#2157): "Enhanced in vitro activity of dianhydrogalactitol (VAL-083) in combination with platinum drugs: Impact of p53 and platinum-resistance," was presented at AACR during the "New Drugs, Therapeutic Targets, and Treatment Approaches" session.

In summary, MD Anderson researchers presented new in vitro data from their studies with VAL-083 indicating that:

VAL-083 induces apoptosis independent of p53 status, and appears to have a distinct mode of action from platinum-based chemotherapies widely used in the treatment of NSCLC and ovarian cancer;
VAL-083 demonstrated ability to circumvent cisplatin-resistance in all ovarian cell lines tested;
VAL-083 was active against NSCLC tumors harboring T790M, p53 and/or KRAS mutations, known to confer resistance to currently available therapies; and
VAL-083 demonstrated super-additivity or synergy in combination with platinum-based chemotherapy.
"These results support VAL-083 as a viable treatment option for refractory NSCLC and ovarian cancer patients failing platinum-based therapy as well as the potential benefit of a VAL-083-platinum combination," said Jeffrey Bacha, DelMar's chairman & CEO.

Dr. Dennis Brown, DelMar's Chief Scientific Officer, added, "The activity of VAL-083 observed in tumors harboring mutations known to be correlated with resistant phenotypes and poor treatment outcomes provides clarity and direction as we advance toward planned clinical trials in NSCLC. We can use these biomarkers for patient selection in a personalized-medicine approach to establish clinical proof-of-concept in specific tumor sub-types representing significant unmet needs within the cancer treatment market."

DelMar previously announced plans to initiate clinical trials with VAL-083 in the treatment of NSCLC in cooperation with Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd., who is to provide funding for the trial in accordance with the terms of a collaboration agreement.

http://www.prnewswire.com/news-releases/delmars-val-083-demonstrates-promise-in-the-treatment-of-non-small-cell-lung-cancer-and-ovarian-cancer-300252824.html